<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126850</url>
  </required_header>
  <id_info>
    <org_study_id>19-05-0624</org_study_id>
    <nct_id>NCT04126850</nct_id>
  </id_info>
  <brief_title>Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease</brief_title>
  <official_title>Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to discover the composition on the microbiome in several sites of the human&#xD;
      body; and to find out the difference in microbiome composition on ocular fluid, blood, and&#xD;
      feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet&#xD;
      and Vogt-Koyanagi-Harada) and idiopathic uveitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiome has been widely studied around the globe, and it is convinced that the gut&#xD;
      microbiome plays an essential role in many human diseases. In a published review showed the&#xD;
      presence of microbes in blood from a patient who suffered from non-communicable disease. The&#xD;
      microbes present in dormant or not-immediately-culturable states as if blood is a 'sterile'&#xD;
      environment. It was argued that the difficulty of culturing microbes from the blood was&#xD;
      coming from the limited understanding of suitable growth/isolation media for the microbes to&#xD;
      be cultured. This limitation can be overcome by the sequenced-based methods for detecting&#xD;
      non-proliferating microbes. The presence of microbes in blood also can be observed by&#xD;
      ultrastructural (microscopic) methods. Through the microscopic observations, it was&#xD;
      witnessing the presence of coccus and bacillus shaped bacteria that present proximity to (Red&#xD;
      Blood Cell) RBCs in sample blood patients with Alzheimer's or Parkinson's Disease. The&#xD;
      presence of microbes in the places other than their normal location state by term&#xD;
      'atopobiosis'. The presence of microbes in blood suspected as a result of translocation&#xD;
      between the gut to the blood.&#xD;
&#xD;
      Therefore, according to the current knowledge of microbiome association and the human&#xD;
      diseases, we are eager to conduct a pilot project that gives a comprehensive picture of the&#xD;
      association between the microbiome and uveitis disease partially non-infectious and&#xD;
      idiopathic uveitis. We will investigate microbiome profiling in the intestinal and&#xD;
      extra-intestinal of uveitis patients before and after treatment to see whether any alteration&#xD;
      of microbial abundance at two distinct clinical conditions partially in uveitis patients with&#xD;
      history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis.&#xD;
      Another objective of this study is to explore any pathogenic microorganism that present in&#xD;
      uveitis patients samples conducted by a sequenced-based method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differential abundant taxonomic groups bacterial</measure>
    <time_frame>0, 6 weeks</time_frame>
    <description>The primer used in this amplicon study is targeted to 16S rRNA gene region V3-V4 to detect bacterial diversity in the samples. The sequencing will be generated by Illumina according to standard protocol. Prior filter is conducted using Prinseq-lite, then chimeric sequences remove using Usearch61 and left over the high quality reads. The (operational taxonomic unit) OTU is picked using bioinformatic tool (Quantitative Insights Into Microbial Ecology - QIIME). Taxonomic classification for de novo OTUs clustering will be generated using open source software package for bioinformatics data processing. Shanon diversity, Simpson index will be examined for calculating alpha diversity. And then we will do identification of differential abundant taxonomic groups. And do analysis correlation network between bacterial genera among two clinical condition (before and after received oral steroid) relatively to health control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection pathogenic microorganism in samples</measure>
    <time_frame>0, 6 weeks</time_frame>
    <description>In this study we are going to use IDseq Portal, a novel bioinformatics platform that designed for detection of microbes from metagenomic data. This analysis will be applied in all types samples (stool, blood, and aqueous humor). We expect to find any specific microbiome (bacterial/fungal/virus) signature in samples patient uveitis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Autoimmune Uveitis</condition>
  <condition>Behçet Disease</condition>
  <condition>Vogt-Koyanagi-Harada Disease</condition>
  <condition>Idiopathic Uveitis</condition>
  <condition>Noninfectious Panuveitis</condition>
  <condition>Anterior Uveitis Idiopathic</condition>
  <condition>Posterior Uveitis</condition>
  <condition>Intermediate Uveitis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Feces&#xD;
&#xD;
        -  Blood&#xD;
&#xD;
        -  Aqueous humor&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-infectious and idiopathic uveitis patients registered from November 2019 at Cipto&#xD;
        Mangunkusumo Hospital, Indonesia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New patient registered at Cipto Mangunkusumo Hospital since November 2019&#xD;
&#xD;
          -  Patient diagnosed with non-infectious uveitis (with Behcet, VKH history)&#xD;
&#xD;
          -  Patient idiopathic uveitis (proven to have negative result by available etiological&#xD;
             uveitis work-ups)&#xD;
&#xD;
          -  Minimum age: 18 years old&#xD;
&#xD;
          -  Experience active inflammation in the past 180 days and or during patient registration&#xD;
             following Standard Uveitis Nomenclature (SUN) guidelines, in at least:&#xD;
&#xD;
               -  equal and or more than 2+ anterior chamber cells&#xD;
&#xD;
               -  equal and or more than 2+ vitreous haze and/or&#xD;
&#xD;
               -  active retinal/choroidal lesions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients had taken probiotics supplement or antibiotics 3 months before sample&#xD;
             collection&#xD;
&#xD;
          -  or who experience prolonged diarrhea or constipation&#xD;
&#xD;
          -  or undergone gastrointestinal surgery&#xD;
&#xD;
          -  having any form of malignancy&#xD;
&#xD;
          -  having a systemic disease such as hypertension, obesity, inflammatory bowel disease,&#xD;
             or diabetes.&#xD;
&#xD;
          -  Disagree to sign informed consent&#xD;
&#xD;
          -  Uveitis is proven to be an infectious origin&#xD;
&#xD;
          -  Pregnant patient&#xD;
&#xD;
          -  Loss to follow up patient&#xD;
&#xD;
        Healthy volunteers are recruited for this study after giving consent with the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  age: 18-50 years old (Man/Woman)&#xD;
&#xD;
          -  having no health complaints or symptoms&#xD;
&#xD;
          -  not in any long term medications&#xD;
&#xD;
          -  having no history of allergy&#xD;
&#xD;
          -  willing to cooperate in the study&#xD;
&#xD;
          -  state of complete physical, mental and social well being&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratna Sitompul, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>RSUPN dr. Cipto Mangunkusumo Hospital (RSCM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ratna Sitompul, Professor</last_name>
    <phone>+628118009911</phone>
    <email>ratna_sitompul@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rina La Distia Nora, PhD</last_name>
    <phone>+62811198910</phone>
    <email>rina.ladistia@ui.ac.id</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RSUPN dr. Cipto Mangunkusumo (Cipto Mangunkusumo Hospital)</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10320</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>RSCM Kirana</last_name>
      <phone>+622131902885</phone>
      <email>kolit.rscmkirana@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Divisi IIM RSCM Kirana</last_name>
      <phone>+6285781170297</phone>
      <email>iim.rscmkirana@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Ratna Sitompul</investigator_full_name>
    <investigator_title>Prof. Dr. dr. Ratna Sitompul, SpM(K)</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Autoimmune Uveitis</keyword>
  <keyword>Vogt-Koyanagi-Harada Disease</keyword>
  <keyword>Behçet Disease</keyword>
  <keyword>Idiopathic Uveitis</keyword>
  <keyword>Metatranscriptomic</keyword>
  <keyword>Amplicon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

